A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients With Endometrioid Intraepithelial Neoplasia

NCT07107334 on ClinicalTrials.gov · last registry update 2026-06-08

A small phase 2 — 20 participants, against a typical 110. Due to report November 2028, alongside 27 other tracked readouts that quarter. Primary outcome, as filed: Time from start of GLP-1RA to clearance of staging hysterectomy. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is approved in the US, but not for cancer — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: RECRUITING
Phase: P2
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: University of Florida
Sponsor type: Other
Enrollment: 20
Started: 2026-04-07
Primary completion: 2028-11 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Time from start of GLP-1RA to clearance of staging hysterectomy

Conditions studied

Endometrioid Endometrial Adenocarcinoma

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.